focus -WSS

focus

author：fashion 2025-10-01 06:00:51 - browse：474

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： STAT Virtual Event: The State of Biosimilars: What to Watch

WSS

New clues to why women have higher risk of autoimmune disorders

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

In early work, researchers turn to CRISPR to treat Alzheimer's

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Medicare drug price negotiation legal challenge met with skepticism

hotspot

focus

Wikipedia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biogen walks away from Aduhelm, years after polarizing approval

The high cost of giving birth even with insurance

Startup Neumora takes a novel depression drug to Phase 3

Hepatitis C has a cure — but many Americans still lack access to it

Philips to halt sales of sleep apnea machines in U.S.

Psychedelics group wrestles with new pharma identity

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Google and Epic fight stronger regulation of AI in health care

focus

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Why you shouldn’t ask, “What country has the best health care?”

Why hospitals are withdrawing from US News rankings

WHO calls for emergency meeting on new China virus, as cases spread

Merck, Johnson & Johnson CEOs will testify on high drug prices

leisure time

leisure time

focus

entertainment